Research Papers:

The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance

Majed Saad Al Fayi, Xiaojun Gou, Shiva S. Forootan, Waseem Al-Jameel, Zhengzheng Bao, Philip R. Rudland, Philip A. Cornford, Syed A. Hussain and Youqiang Ke _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:82783-82797. https://doi.org/10.18632/oncotarget.12635

Metrics: PDF 2305 views  |   HTML 2346 views  |   ?  


Majed Saad Al Fayi1,3, Xiaojun Gou2, Shiva S. Forootan1, Waseem Al-Jameel1, Zhengzheng Bao1, Philip R. Rudland4, Philip A. Cornford1, Syed A. Hussain1, Youqiang Ke1

1Molecular Pathology Laboratory, Department of Molecular and Clinical Cancer Medicine, Liverpool University, the Cancer Research Centre Building, Liverpool, United Kingdom

2Sichuan Antibiotics Industrial Institute, Chengdu University, Chengdu, China

3Department of Medical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Kingdom of Saudi Arabia

4Department of Biochemistry, Liverpool University, Liverpool, United Kingdom

Correspondence to:

Youqiang Ke, email: [email protected]

Keywords: prostate cancer, FABP9, gleason scores, prognosis, PSA

Received: June 17, 2016    Accepted: September 28, 2016    Published: October 13, 2016


In contrast to numerous studies conducted to investigate the crucial role of fatty acid binding protein 5 (FABP5) in prostate cancer, investigations on the possible involvement of other FABPs are rare. Here we first measured the mRNA levels of 10 FABPs in benign and malignant prostate cell lines and identified the differentially expressed FABP6 and FABP9 mRNAs whose levels in all malignant cell lines were higher than those in the benign cells. Thereafter we assessed the expression status of FABP6 and FABP9 in both prostate cell lines and in human tissues. FABP6 protein was overexpressed only in 1 of the 5 malignant cell lines and its immunostaining intensities were not significantly different between benign and malignant prostate tissues. In contrast, FABP9 protein was highly expressed in highly malignant cell lines PC-3 and PC3-M, but its level in the benign PNT-2 and other malignant cell lines was not detectable. When analysed in an archival set of human prostate tissues, immunohistochemical staining intensity for FABP9 was significantly higher in carcinomas than in benign cases and the increase in FABP9 was significantly correlated with reduced patient survival times. Moreover, the increased level of staining for FABP9 was significantly associated with the increased joint Gleason scores (GS) and androgen receptor index (AR). Suppression of FABP9 expression in highly malignant PC3-M cells inhibited their invasive potential. Our results suggest that FABP9 is a valuable prognostic marker to predict the outcomes of prostate cancer patients, perhaps by playing an important role in prostate cancer cell invasion.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12635